An experimental vaccine designed to prevent pancreatic cancer has shown promising results in a Phase 1 human trial conducted at Johns Hopkins School of Medicine. The vaccine, known as mKRAS-VAX, targeted common mutations in the KRAS gene, which are implicated in more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases, the most common and aggressive form of the disease.

The study, published in the journal Cancer Discovery, involved 20 participants who had an inherited risk for PDAC and imaging abnormalities, such as pancreatic cysts, but had not yet been diagnosed with cancer. Participants received four doses of the vaccine over several weeks, followed by a booster.

Immune Response and Safety

The mKRAS-VAX vaccine successfully triggered a targeted immune response in 18 out of the 20 participants, representing 90% of those studied. Researchers observed an average 18-fold increase in immune activity, with half of the participants responding to all six KRAS mutations included in the vaccine. The vaccine also generated T cells capable of attacking abnormal cells and providing long-term immune memory.

During the trial, the vaccine was found to be safe and well-tolerated. Participants experienced only mild side effects, such as injection-site reactions and temporary flu-like symptoms.

Preliminary Outcomes and Future Directions

While the primary goal of this Phase 1 trial was to assess safety, preliminary observations after approximately 16.5 months of follow-up indicated that none of the participants developed pancreatic cancer. Additionally, 37.5% of those vaccinated experienced a reduction or disappearance of their pancreatic cysts. Researchers noted that these outcomes, particularly the cyst regression, were observed in association with the vaccine-induced KRAS-specific T-cell responses.

Study co-authors emphasized that larger studies are necessary to confirm these findings and demonstrate clinical efficacy. The study's limitations include its small sample size and its design, which was not intended to determine effectiveness. However, the researchers consider this a significant first proof of concept for using vaccines to intercept pancreatic cancer in humans. They highlighted the importance of prevention and interception strategies, especially for cancers with increasing incidence and lacking effective early detection methods. Further research is needed to optimize vaccine approaches, targets, and timing.